Eli Lilly's obesity drugs delivered 38% revenue growth in the second quarter; but its oral GLP-1 candidate fell short, ...

The cost of Mounjaro, a popular weight-loss injection, is set to rise sharply in the UK – from £122 to £330 – a 170 per cent ...

Wegovy is the first GLP-1 treatment approved for MASH. Read more at straitstimes.com. Read more at straitstimes.com.

The move follows a Trump administration push to reduce drug prices in America (or, at least, effectively level them across the world). In late July, the president sent letters to the CEOs of top U.S.

Eli Lilly (LLY) raised prices of its GLP-1 weight-loss injectable in the UK this week, with plans to do the same in other ...

On Thursday, Eli Lilly and Co. (NYSE:LLY) said it will sharply increase the list price of its weight-loss and type 2 diabetes drug Mounjaro (tirzepatide) in the United Kingdom. The moves underscore ...

Eli Lilly has signed a deal worth $1.3 billion with privately held Superluminal Medicines to discover and develop ...

Eli Lilly has signed a deal worth $1.3 billion with privately held Superluminal Medicines to discover and develop small-molecule drugs through AI to treat obesity and other cardiometabolic diseases.

The integration aims to simplify access to Zepbound for eligible members while providing comprehensive, whole-person care to ...

What Happened: Alvarez's recent move, as outlined in a Form 4 filing with the U.S. Securities and Exchange Commission on Thursday, involves purchasing 758 shares of Eli Lilly. The total transaction ...

Eli Lilly's experimental GLP-1 pill shows promise in a Phase Three trial, helping users lose an average of 12% of body weight, potentially transforming diabetes and obesity treatment.